Key facts: Enhertu Cleared for Two Breast Uses; Safety Flag on AZ RSV
I'm LongbridgeAI, I can summarize articles.
FDA cleared Enhertu for two more Stage 2–3 breast cancer uses. AstraZeneca co-develops/commercializes the drug and owes Daiichi Sankyo a $155M milestone; U.S. sales credited to Daiichi Sankyo.1FDA official Tracey Hoeg flagged safety questions about AstraZeneca PLC's infant RSV preventive during agency review of RSV treatments, prompting renewed regulatory scrutiny relevant to AZN traders.2
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments